SCHEMBL20280271

SCHEMBL20280271

CC(C=O)c1cc(Cl)ccc1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 4/20 0.42
HTT P42858 2/20 0.42
LMNA P02545 1/20 0.42
TDP1 Q9NUW8 3/20 0.41
ALDH1A1 P00352 5/20 0.35
TSHR P16473 2/20 0.35
CYP3A4 P08684 1/20 0.35
HSD17B10 Q99714 1/20 0.35
MEN1 O00255 4/20 0.35
KMT2A Q03164 4/20 0.35
MAPT P10636 2/20 0.35
MAPK1 P28482 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
ERN1 O75460 1/20 0.34
GABRA1 P14867 1/20 0.33
GABRB1 P18505 1/20 0.33
PSEN1 P49768 1/20 0.33
PSEN2 P49810 1/20 0.33
APH1B Q8WW43 1/20 0.33
NCSTN Q92542 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL838659 0.84 TP53 (0.57) TP53HTTLMNATDP1CYP3A4
SCHEMBL27624253 0.82 CYP3A4 (0.41) TP53HTTLMNATDP1ALDH1A1
SCHEMBL27624284 0.82 PSEN1 (0.41) TP53HTTLMNATDP1MEN1
SCHEMBL28796016 0.81 CYP3A4 (0.43) TP53HTTLMNAALDH1A1TSHR
SCHEMBL17755251 0.81 TP53 (0.40) TP53HTTLMNATDP1ALDH1A1
SCHEMBL27542435 0.81 ALDH1A1 (0.39) ALDH1A1TSHRMEN1KMT2AMAPT
SCHEMBL27655281 0.81 HTT (0.36) TP53HTTLMNATDP1ALDH1A1
SCHEMBL7519487 0.81 KMT2A (0.51) TP53HTTLMNATDP1ALDH1A1
SCHEMBL27643614 0.78 LMNA (0.41) TP53HTTLMNATDP1TSHR
SCHEMBL479932 0.78 HTT (0.46) HTTTDP1ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210040049-A1 ANTI-HCMV COMPOSITIONS AND METHODS EVRYS BIO, LLC (US) 2021-02-11 US disclosed
US-10723708-B2 Anti-HCMV compositions and methods EVRYS BIO, LLC (US) 2020-07-28 US disclosed
US-20180170884-A1 ANTI-HCMV COMPOSITIONS AND METHODS FORGE LIFE SCIENCE, LLC 2018-06-21 US disclosed
US-20180170884-A1 ANTI-HCMV COMPOSITIONS AND METHODS FORGE LIFE SCIENCE, LLC 2018-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10723708-B2 Anti-HCMV compositions and methods RPL35, RPL7, RPL5 TP53 511/4885HTT 3200/4885LMNA 1477/4885
US-20210040049-A1 ANTI-HCMV COMPOSITIONS AND METHODS RPL35, RPL7, RPL5 TP53 511/4885HTT 3200/4885LMNA 1477/4885
US-20180170884-A1 ANTI-HCMV COMPOSITIONS AND METHODS RPL35, RPL7, RPL5 TP53 511/4885HTT 3200/4885LMNA 1477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.